The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
News|Articles|January 2, 2005
- Pharmaceutical Technology-01-02-2005
- Volume 29
- Issue 1
Method Development of Swab Sampling for Cleaning Validation of a Residual Active Pharmaceutical Ingredient
A swab-sampling method was developed for cleaning validation of a residual active pharmaceutical ingredient in samples collected after cleaning the sampling suite. A summary of the strategies and results of the method development is presented.
Advertisement
Articles in this issue
over 21 years ago
An Overview of the Effect of Moisture on Compaction and Compressionover 21 years ago
The Pipeline Crisisover 21 years ago
The Outsourcing Advantages in Formulation Developmentover 21 years ago
Drug Safety and Access Top Policy Concerns for 2005over 21 years ago
Comparison of EP "Heavy Metals" Test with USP "Conductivity" Testover 21 years ago
Patheon Places Big Bet with Mova Acquisitionover 21 years ago
January 2005over 21 years ago
In the Spotlight-January 2005Advertisement
Related to this article
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Christy Owings, Thermo Fisher, on why early supply chain partnership and site visits prevent costly eCOA and clinical trial delays.
Christy Owings, Thermo Fisher, on how AI complements clinical supply chain expertise, streamlines site logistics, and tracks shifting biotech markets.
Christy Owings, Thermo Fisher, speaks on why importer of record strategy and vetted local partners are key to reliable clinical trial supply chains.
Advertisement
Advertisement